JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.C000113200 on March 15, 2000
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
275/19/14013    most recent
C000113200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Takeda, K.
Right arrow Articles by Shibahara, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Takeda, K.
Right arrow Articles by Shibahara, S.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

J Biol Chem, Vol. 275, Issue 19, 14013-14016, May 12, 2000

ACCELERATED PUBLICATION
Induction of Melanocyte-specific Microphthalmia-associated Transcription Factor by Wnt-3a*

Kazuhisa Takeda, Ken-ichi Yasumoto, Ritsuko TakadaDagger , Shinji TakadaDagger §, Ken-ichi Watanabe, Tetsuo Udono, Hideo Saito, Kazuhiro Takahashi, and Shigeki Shibahara

From the Department of Molecular Biology and Applied Physiology, Tohoku University School of Medicine, Aoba-ku, Sendai, Miyagi 980-8575, Japan, Dagger  Kondoh Differentiation Signaling Project, ERATO, Japan Science and Technology Corporation (JST), 14 Yoshidakawaramachi, Sakyo-ku, Kyoto 606-8305, Japan, and § Center for Molecular and Developmental Biology, Graduate School of Science, Kyoto University, Sakyo-ku, Kyoto 606-8502, Japan

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES

Microphthalmia-associated transcription factor (Mitf) plays a critical role in the development of neural crest-derived melanocytes. Here, we show that exogenously added Wnt-3a protein, an intercellular signaling molecule, up-regulates the expression of endogenous melanocyte-specific Mitf (Mitf-M) mRNA in cultured melanocytes. The melanocyte-specific promoter of the human MITF gene (MITF-M promoter) contains a functional LEF-1-binding site, which is bound in vitro by LEF-1 and confers the preferential expression on a reporter gene in melanocytes and melanoma cells, as judged by the transient transfection assays. Moreover, the LEF-1-binding site is required for the transactivation of a reporter gene by LEF-1, beta -catenin, or their combination. Exogenously added Wnt-3a protein also transactivates the MITF-M promoter via the LEF-1-binding site; this activation was abolished when a dominant-negative form of LEF-1 was coexpressed. These results suggest that Wnt-3a signaling recruits beta -catenin and LEF-1 to the LEF-1-binding site of the MITF-M promoter. Therefore, the present study identifies Mitf-M/MITF-M as a direct target of Wnt signaling.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES

Microphthalmia-associated transcription factor (Mitf),1 encoded by the mouse Mitf locus, plays a critical role in the differentiation of various cell types, including neural crest-derived melanocytes, bone marrow-derived mast cells and osteoclasts, and optic cup-derived retinal pigment epithelium (RPE) (1-3). Mitf and its human counterpart, MITF, contain a basic helix-loop-helix leucine zipper structure, which is required for DNA binding and dimer formation. MITF consists of at least five isoforms with distinct amino termini, called MITF-A, -B, -C, -H, and -M (4-6). The amino termini of these isoforms are encoded by a separate first exons, and each exon 1 is under the control of a unique promoter (6). Among these isoforms, MITF-M/Mitf-M is exclusively expressed in melanocytes and melanoma cells of neural crest origin (4, 5, 7). In fact, the 5'-flanking region of the first exon, coding for the amino terminus of MITF-M, shows the melanocyte-specific promoter function (8), here referred to as the MITF-M promoter. In contrast, other MITF isoforms are widely expressed in many cell types (4, 5).

MITF-M/Mitf-M efficiently transactivates the melanogenesis enzyme genes, such as tyrosinase and tyrosinase-related protein-1, in cultured cells (9-14) and can convert a fibroblast cell line to the cells expressing tyrosinase and tyrosinase-related protein-1 (15). The mutations in the MITF/Mitf gene were found in patients with auditory pigmentary syndromes such as Waardenburg syndrome type 2 (16-18), as well as in many Mitf mutant mice (2). These affected individuals mainly exhibit hypopigmentation and hearing impairment, caused by the lack of pigment cells in the skin and inner ear. Moreover, the MITF-M promoter is up-regulated by PAX3 (19), a transcription factor with a paired-homeodomain, in which the gene is responsible for Waardenburg syndrome types 1 and 3 (17). Moreover, the essential requirement of Mitf-M in melanocyte development was verified by the molecular lesion of the black-eyed white Mitfmi-bw mice (20), which are characterized by a completely white coat color, deafness, and normally pigmented RPE (21). In Mitfmi-bw mice, the insertion of an L1 retrotransposable element in intron 3 lead to complete repression of Mitf-M mRNA expression and to a reduction of Mitf-A and Mitf-H mRNAs expression (20). Taken together, these results indicate that MITF-M/Mitf-M is a key regulator of the melanocyte development but is dispensable for RPE development. However, the mechanism of differentiation of neural crest cells toward melanocytes is not well understood.

Wnt proteins, which are secreted cysteine-rich glycoproteins, have been established as developmentally important signaling molecules (22). Particularly, Wnt-1 and Wnt-3a are required for the expansion of neural crest precursors (23, 24) and for determining the fate of neural crest cells during early development (25). In fact, targeted disruption of the Wnt-1 and Wnt-3a genes in the mouse causes deficiency of neural crest derivatives, including melanocytes (24). On the other hand, mutant mice lacking Wnt-1 or Wnt-3a show no noticeable deficiency of neural crest derivatives from the dorsal neural tube (26, 27). These results suggest a redundant role for Wnt-1 and Wnt-3a signaling in the differentiation of neural crest precursors. Wnt-3a is expressed in pluripotent ectoderm cells of the primitive streak during gastrulation (27). The onset of Wnt-3a expression is detected at embryonic day 7.5 (27), which precedes the onset of Mitf expression in neural crest cells (9.5-10.5 days) (28). These results suggest that Wnt-3a is a good candidate for regulating the differentiation of neural crest cells toward melanocytes. The signals evoked by Wnt proteins lead to intracellular accumulation of beta -catenin, a key downstream component of the Wnt signaling pathway (22, 29). beta -Catenin then activates the target genes through interaction with a member of the LEF-1/TCF transcription factors, containing a high mobility group domain. Thus, LEF-1/TCF transcription factors mediate a nuclear response to Wnt signals.

Here, we show that exogenously added Wnt-3a protein induces endogenous Mitf-M mRNA in cultured melanocytes. In addition, we identify the functional LEF-1-binding site in the MITF-M promoter and provide evidence that Wnt-3a signaling recruits beta -catenin and LEF-1 to the MITF-M promoter, which leads to increased transcription from the MITF-M promoter. Therefore, the present study shows a direct link between Wnt signaling and Mitf-M/MITF-M expression.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES

Wnt-3a Conditioned Medium-- The mouse fibroblast L cells, constitutively expressing mouse Wnt-3a cDNA, were seeded at a density of 1 × 106 in a 94-mm dish containing a 1:1 mixture of Dulbecco's modified Eagle's medium and Ham's F12 supplemented with 10% fetal calf serum (30). After 3 days of culture, cells were refed with fresh medium and incubated for 1 more day, and the cultured media were collected as conditioned media, referred to as Wnt3a/L-CM. Wnt3a/L-CM was estimated to contain about 400 ng/ml of Wnt-3a protein (30). Conditioned media, neo/L-CM, were also prepared from the cultures of control L cells that were stably transfected with a vector plasmid as described previously (30).

Northern Blot Analysis-- Melan-a murine-immortalized melanocytes, a gift from D. C. Bennett (31), were grown in minimum essential medium supplemented with 10% fetal calf serum and 200 nM phorbol 12-myristate 13-acetate. Melan-a cells, maintained in a 3.5-cm dish containing 1 ml of the medium, were treated with Wnt3a/L-CM or neo/L-CM for 24 h. The final concentration of Wnt-3a was about 40 ng/ml. Total RNA was prepared from the treated Melan-a cells of two dishes and subjected to Northern blot analysis as described previously (15). The ClaI/EcoRI DNA fragment of human MITF cDNA (32) and glyceraldehyde 3'-phosphate dehydrogenase cDNA (positions 601-1052) (33) were labeled with [alpha -32P]dCTP using a BcaBEST labeling kit (Takara) and were used as hybridization probes.

Plasmid Preparation-- A wild-type reporter plasmid, pGL3-MITF/M, was constructed as follows. The BamHI/XhoI fragment containing the 2.2-kilobase pair human MITF-M pomoter was isolated from pHMIL1 (8) and ligated to pGL3-Basic (Promega), linearized by the digestion with SmaI and XhoI. Prior to ligation, the BamHI site had been converted to a blunt end by a filling-in reaction. A mutant construct, pGL3-MITF/M(m195), was constructed from pGL3-MITF/M by the QuickChange site-directed mutagenesis kit (Stratagene) according to the manufacturer's instructions. The mutant primer used was the synthetic oligonucleotide (positions -215 to -174) carrying the base changes at positions -196 and -195. Thus, pGL3-MITF/M(m195) carries the GT nucleotides instead of the original TG nucleotides at position -195 (8).

Human LEF-1 cDNA, a gift from K. A. Jones (34), was subcloned in the pRc/CMV eukaryotic expression vector (Invitrogen), yielding pRc/CMV-LEF-1. A dominant-negative form of LEF-1, DNLEF-1, lacks the 26 amino acid residues near the amino terminus (amino acid positions 2-27); its cDNA was made by polymerase chain reaction and subcloned in pRc/CMV, generating pRc/CMV-DNLEF-1. beta -Catenin cDNA was synthesized by reverse-transcribed polymerase chain reaction and subcloned in pRc/CMV, yielding pRc/CMV-beta -catenin. TOPFLASH and FOPFLASH, gifts from M. van de Wetering and H. Clevers (35), contain the LEF-1 responsive elements and the mutated LEF-1 responsive elements, respectively.

Electrophoretic Mobility Shift Assay (EMSA)-- LEF-1 protein was produced from pRc/CMV-LEF-1 by in vitro transcription/translation reaction using a TNT T7-coupled reticulocyte lysate system kit (Promega). The production of LEF-1 protein was assessed by electrophoresis of the translation products labeled with [35S]methionine. The wild-type oligonucleotide of the MITF promoter sequence from nucleotides -215 to -174 (5'-CTGACAGTGAGTTTGACTTTGATAGCTCGTCACTTAAAAAGG-3'/3'-GACTGTCACTCAAACTGAAACTATCGAGCAGTGAATTTTTCC-5') was end-labeled with [gamma -32P]ATP and T4 polynucleotide kinase and used as a probe. EMSA was carried out as described previously (18).

Transfection and Luciferase Assay-- HeLa cells were grown in minimum essential medium supplemented with 10% fetal calf serum. HMV-II melanoma cells were grown in Ham's F12 medium supplemented with 10% fetal calf serum. HeLa cells were seeded at 60-80% confluency in a 3.5-cm dish 18-24 h prior to transfection. Transfection was performed by the calcium phosphate precipitation method (18). The amount of DNA used for transfection was 6 µg, consisting of 0.5 µg of each test plasmid and pCH110, beta -galactosidase expression vector under control of SV40 early promoter as an internal control, and pBluescript SK(+) as a filler. Transfection was also carried out in HMV-II melanoma cells as described above. After 24 h, transfected cells were harvested, and the activities of luciferase and beta -galactosidase were measured as described previously (13). Luciferase activity was normalized by beta -galactosidase activity.

Melan-a cells were transfected by FuGene 6 transfection reagent (Roche Molecular Biochemicals) according to the manufacturer's instructions. The amount of DNA used for transfection was 1.5 µg, consisting of 0.5 µg of each test plasmid and pCH110, with pBluescript SK(+) as a filler. After 4 h, Wnt3a/L-CM or neo/L-CM was added to each culture medium of transfected Melan-a cells. Cells were then incubated for 24 h and harvested.

    RESULTS AND DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES

To assess the hypothesis that Wnt signaling regulates the expression of MITF-M/Mitf-M, we analyzed the effect of Wnt-3a protein on Mitf-M mRNA expression in cultured melanocytes. Accordingly, Melan-a immortalized melanocytes were treated with Wnt3a/L-CM containing Wnt-3a protein or neo/L-CM for 24 h (Fig. 1). The treatment with Wnt3a/L-CM increased Mitf-M mRNA by 24 h (lane 1), whereas the treatment with neo/L-CM did not (lane 2). Thus, Wnt-3a induces the expression of endogenous Mitf-M mRNA, supporting the notion that Wnt signaling is involved in melanocyte differentiation.


View larger version (54K):
[in this window]
[in a new window]
 
Fig. 1.   Induction of Mitf mRNA expression in melanocytes by Wnt-3a protein. Shown is an autoradiogram of the Northern blot hybridized with MITF cDNA. Each lane contained 7 µg of RNA prepared from Melan-a cells treated for 24 h with Wnt3a/L-CM containing Wnt-3a (lane 1) or neo/L-CM (lane 2). The untreated control (treated for 0 h) is also shown (lane 3). Glyceraldehyde 3'-phosphate dehydrogenase (G3PDH) mRNA was detected as an internal control. 18 and 28 S ribosomal RNAs are shown by arrowheads.

Wnt signaling activates the target genes through the interaction of beta -catenin and a member of the LEF-1/TCF transcription factors. The consensus DNA sequence recognized by LEF-1/TCF transcription factors is CTTTGA/TA/T (29), and the MITF-M promoter contains a putative LEF-1/TCF-binding site, CTTTGAT (positions -199 to -193), which agrees with the consensus sequence (Fig. 2A). The same sequence motif is conserved at a similar position in the mouse Mitf-M promoter.2 To assess the function of the putative LEF-1/TCF-binding site in the MITF-M promoter, we compared the expression levels of pGL3-MITF/M in HMV-II human melanoma cells with those of pGL3-MITF/M(m195), containing the altered LEF-1/TCF site, CTTGTAT (Fig. 2B). These base changes were expected to reduce the MITF-M promoter activity, because the Wnt signaling pathway is activated in many melanoma cells due to beta -catenin mutation (36). In fact, the expression level of pGL3-MITF/M(m195) was lower than that of pGL3-MITF/M, whereas the expression levels of these two constructs were similarly lower in HeLa cervical cancer cells. These results suggest that the CTTTGAT motif is involved in MITF-M promoter activity in melanoma cells. The significant luciferase activity detected with pGL3-MITF/M(m195) in melanoma cells may be due to the presence of other melanocyte-specific enhancers present in the MITF-M promoter.


View larger version (14K):
[in this window]
[in a new window]
 
Fig. 2.   Transactivation of the MITF-M promoter by LEF-1 and beta -catenin. A, schematic representation of the test constructs. A putative LEF-1/TCF site is underlined in the MITF-M promoter carried by pGL3-MITF/M, and the base changes in the pGL3-MITF/M(m195) are shown by lowercase letters. The arrow indicates the direction of transcription, and the nucleotide residues are numbered from the transcription start site. The positions of the PAX-3-binding site (PAX3) and the cAMP response element (CRE) are shown schematically. B, functional analysis of the putative LEF-1/TCF-binding site. HMV-II melanoma and HeLa cervical cancer cells were transfected with pGL3-MITF/M or pGL3-MITF/M(m195). Relative luciferase activity is shown as the ratio to the normalized luciferase activity in HeLa cells transfected with pGL3-MITF/M. The data shown are the means ± S.D. of three independent experiments. C, effects of LEF-1 and beta -catenin. HeLa cervical cancer cells were transfected with pGL3-MITF/M (shown as wild) or pGL3-MITF/M(m195), containing the altered LEF-1/TCF-binding site (mutant), and effector plasmids pRc/CMV-LEF-1, pRc/CMV-beta -catenin, or both. Relative luciferase activity is shown as the ratio to the normalized luciferase activity obtained with pGL3-MITF/M. The data shown are the means ± S.D. of three independent experiments.

We then performed cotransfection assays in HeLa cervical cancer cells to test the possibility that the LEF-1/TCF family is involved in regulation of the MITF-M promoter (Fig. 2C). Expression of either LEF-1 or beta -catenin significantly increased the luciferase activity under the control of the MITF-M promoter. The coexpression of beta -catenin and LEF-1 synergistically increased the luciferase activity, which was higher than the degree of activation caused by LEF-1 or beta -catenin. In contrast, the introduction of mutation at the putative LEF-1 site completely inhibited the increase in luciferase activity caused by LEF-1, beta -catenin, or their combination (Fig. 2C). These results suggest that the CTTTGAT motif of the MITF-M promoter represents a functional LEF-1-binding site.

To confirm whether LEF-1 protein binds to the CTTTGAT motif of the MITF-M promoter, we carried out EMSA. The in vitro translation of LEF-1 mRNA was confirmed by autoradiography of 35S-labeled LEF-1 protein (data not shown). The synthetic LEF-1-binding site was specifically bound by the in vitro translated LEF-1 protein (Fig. 3, lane 1). The formation of this complex was inhibited by competitor oligonucleotide containing the CTTTGAT motif but not by the mutant oligonucleotide containing the CTTGTAT motif (lanes 2 and 3). Taken together, these results indicate that LEF-1 recognizes the CTTTGAT motif of the MITF-M promoter. These results are consistent in part with the recent report showing that the LEF-1/TCF-binding sites of the promoter region of the Nacre, a zebrafish homolog of MITF, is required for pigment cell-specific expression of a reporter gene in vivo (37).


View larger version (71K):
[in this window]
[in a new window]
 
Fig. 3.   LEF-1 binds in vitro to the CTTTGAT motif of the MITF-M promoter. LEF-1 protein was translated from pRc/CMV-LEF-1-derived mRNA in reticulocyte lysate. The binding probe was the 32P end-labeled oligonucleotide of the MITF-M promoter region, containing the CTTTGAT motif. The labeled probe was mixed with the lysate containing the translated LEF-1 protein (lane 1) or the LEF-1 protein plus unlabeled mutant-type DNA (lane 2) or unlabeled wild-type DNA (lane 3). These competitors were added to the reaction mixture at a 1,000-fold molar excess over the input probe. The upper arrow indicates the LEF-1/DNA complex. The reticulocyte lysate containing the translation products derived from pRc/CMV was also subjected to EMSA as a negative control (lane 4).

Finally, we assessed the effects of Wnt-3a protein on the MITF-M promoter activity in Melan-a cells (Fig. 4). In this series of experiments, Melan-a immortalized melanocytes were chosen because this cell line was more sensitive to Wnt-3a treatment than HMV-II melanoma cells, as judged by transient expression assays with the test plasmid TOPFLASH, containing multiple LEF-1 responsive elements (data not shown). Such a difference in sensitivity to Wnt-3a suggests that a component(s) of the Wnt signaling pathway, such as beta -catenin, may be constitutively activated in HMV-II melanoma cells.


View larger version (10K):
[in this window]
[in a new window]
 
Fig. 4.   Activation of the MITF-M promoter by Wnt-3a protein. Melan-a cells were transfected with pGL3-MITF/M or pGL3-MITF/M(m195) with or without pRc/CMV-DNLEF-1. Duplicate cultures of given transfected cells were then treated with Wnt3a/L-CM (+) or neo/L-CM (-) for 24 h. Relative luciferase activity is shown as the ratio to that obtained with pGL3-MITF/M alone. The data shown are the means ± S.D. of three independent experiments.

Melan-a cells were transfected with pGL3-MITF/M or pGL3-MITF/M(m195) and then treated with either Wnt3a/L-CM or neo/L-CM. Wnt3a/L-CM increased the expression of pGL3-MITF/M by about 2.5-fold. To confirm that this increase was dependent on Wnt signaling, we cotransfected the expression plasmid of a dominant-negative form of LEF-1, pRc/CMV-DNLEF-1. The dominant-negative LEF-1 lacks the amino-terminal beta -catenin interaction domain and is expected to inhibit Wnt signaling. The observed activation by Wnt3a/L-CM was completely inhibited when the dominant-negative LEF-1 was coexpressed. Furthermore, the expression level of pGL3-MITF/M(m195) was lower than that of a wild-type construct, pGL3-MITF/M, and was not significantly increased by treatment with Wnt3a/L-CM. These results indicate that the LEF-1 site is necessary and sufficient for the activation of the MITF-M promoter by Wnt-3a signaling. The data all support the interpretation of a direct effect by Wnt-3a, but there is a possibility that a certain factor other than Wnt-3a in the conditioned medium from the Wnt-3a transfectants could contribute to the LEF-1-dependent activation. Further study with Wnt-3a neutralizing antibodies will be required to address this issue.

The MITF-M promoter is functional exclusively in melanocyte-lineage cells (6, 8) and is up-regulated via the separate cis-acting elements by PAX3 (19) and by alpha -melanocyte-stimulating hormone signaling (38) (see Fig. 2A). Here, we provide evidence that Wnt-3a signal activates the MITF-M promoter through the LEF-1-binding site. Thus, multiple signals appear to converge on the MITF-M promoter, leading to the up-regulation of MITF-M expression, a key regulator for the melanogenesis enzyme genes. The expression levels of Pax3 mRNA were reduced in the double knock-out mouse of the Wnt-1 and Wnt-3a genes (24). It is therefore conceivable that Wnt signals may also up-regulate Mitf-M/MITF-M expression through Pax3.

In summary, Wnt-3a protein induces Mitf-M mRNA expression in melanocytes and activates the MITF-M promoter by recruiting LEF-1 and beta -catenin to the LEF-1-binding site. Thus, MITF-M/Mitf-M is a direct target gene of Wnt signaling in humans and mice.

    ACKNOWLEDGEMENTS

We thank D. Bennett for Melan-a cells, K. A. Jones for LEF-1 cDNA, and M. van de Wetering and H. Clevers for pTOPFLASH and pFOPFLASH.

    FOOTNOTES

* This work was supported in part by grants-in-aid for scientific research (B), for exploratory research, and for encouragement of young scientist (to K. Y.) from the Ministry of Education, Science, Sports and Culture of Japan. This work was also supported in part by the Nakatomi Foundation and the Kao Foundation for Arts and Sciences.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

To whom correspondence should be addressed. Tel.: 81-22-717-8117; Fax: 81-22-717-8118; E-mail: shibahar@mail.cc.tohoku.ac.jp.

Published, JBC Papers in Press, March 15, 2000, DOI 10.1074/jbc.C000113200

2 K. Takeda, K. Yasumoto, K. Watanabe, T. Udono, H. Saito, K. Takahashi, and S. Shibahara, unpublished observations.

    ABBREVIATIONS

The abbreviations used are: Mitf, microphthalmia-associated transcription factor; Mitf-M, melanocyte-specific Mitf; EMSA, electrophoretic mobility shift assay; RPE, retinal pigment epithelium; CMV, cytomegalovirus.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES

1. Hodgkinson, C. A., Moore, K. J., Nakayama, A., Steingrimsson, E., Copeland, N. G., Jenkins, N. A., and Arnheiter, H. (1993) Cell 74, 395-404
2. Steingrimsson, E., Moore, K. J., Lamoreux, M. L., Ferre, D. A. A. R., Burley, S. K., Zimring, D. C., Skow, L. C., Hodgkinson, C. A., Arnheiter, H., Copeland, N. G., et al.. (1994) Nat. Genet. 8, 256-263
3. Stechschulte, D. J., Sharma, R., Dileepan, K. N., Simpson, K. M., Aggarwal, N., Clancy, J., Jr., and Jilka, R. L. (1987) J. Cell. Physiol. 132, 565-570
4. Amae, S., Fuse, N., Yasumoto, K., Sato, S., Yajima, I., Yamamoto, H., Udono, T., Durlu, Y. K., Tamai, M., Takahashi, K., and Shibahara, S. (1998) Biochem. Biophys. Res. Commun. 247, 710-715
5. Fuse, N., Yasumoto, K., Takeda, K., Amae, S., Yoshizawa, M., Udono, T., Takahashi, K., Tamai, M., Tomita, Y., Tachibana, M., and Shibahara, S. (1999) J. Biochem. (Tokyo) 126, 1043-1051
6. Udono T., Yasumoto, K., Takeda K., Amae S., Watanabe K., Saito H., Fuse N., Tachibana M., Takahashi K., Tamai M., and Shibahara S. (2000) Biochim. Biophys. Acta, in press
7. Yasumoto, K., Amae, S., Udono, T., Fuse, N., Takeda, K., and Shibahara, S. (1998) Pigm. Cell Res. 11, 329-336
8. Fuse, N., Yasumoto, K., Suzuki, H., Takahashi, K., and Shibahara, S. (1996) Biochem. Biophys. Res. Commun. 219, 702-707
9. Hemesath, T. J., Steingrimsson, E., McGill, G., Hansen, M. J., Vaught, J., Hodgkinson, C. A., Arnheiter, H., Copeland, N. G., Jenkins, N. A., and Fisher, D. E. (1994) Genes Dev. 8, 2770-2780
10. Aksan, I., and Goding, C. R. (1998) Mol. Cell. Biol. 18, 6930-6938
11. Bentley, N. J., Eisen, T., and Goding, C. R. (1994) Mol. Cell. Biol. 14, 7996-8006
12. Yasumoto, K., Yokoyama, K., Shibata, K., Tomita, Y., and Shibahara, S. (1994) Mol. Cell. Biol. 14, 8058-8070
13. Yasumoto, K., Mahalingam, H., Suzuki, H., Yoshizawa, M., and Yokoyama, K. (1995) J. Biochem. (Tokyo) 118, 874-881
14. Yasumoto, K., Yokoyama, K., Takahashi, K., Tomita, Y., and Shibahara, S. (1997) J. Biol. Chem. 272, 503-509
15. Tachibana, M., Takeda, K., Nobukuni, Y., Urabe, K., Long, J. E., Meyers, K. A., Aaronson, S. A., and Miki, T. (1996) Nat. Genet. 14, 50-54
16. Tassabehji, M., Newton, V. E., and Read, A. P. (1994) Nat. Genet. 8, 251-255
17. Tassabehji, M., Newton, V. E., Liu, X. Z., Brady, A., Donnai, D., Krajewska-Walasek, M., Murday, V., Norman, A., Obersztyn, E., Reardon, W., et al.. (1995) Hum. Mol. Genet. 4, 2131-2137
18. Nobukuni, Y., Watanabe, A., Takeda, K., Skarka, H., and Tachibana, M. (1996) Am. J. Hum. Genet. 59, 76-83
19. Watanabe, A., Takeda, K., Ploplis, B., and Tachibana, M. (1998) Nat. Genet. 18, 283-286
20. Yajima, I., Sato, S., Kimura, T., Yasumoto, K., Shibahara, S., Goding, C. R., and Yamamoto, H. (1999) Hum. Mol. Genet. 8, 1431-1441
21. Motohashi, H., Hozawa, K., Oshima, T., Takeuchi, T., and Takasaka, T. (1994) Hear. Res. 80, 10-20
22. Cadigan, K. M., and Nusse, R. (1997) Genes Dev. 11, 3286-3305
23. Saint-Jeannet, J. P., He, X., Varmus, H. E., and Dawid, I. B. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 13713-13718
24. Ikeya, M., Lee, S. M., Johnson, J. E., McMahon, A. P., and Takada, S. (1997) Nature 389, 966-970
25. Dorsky, R. I., Moon, R. T., and Raible, D. W. (1998) Nature 396, 370-373
26. Thomas, K. R., and Capecchi, M. R. (1990) Nature 346, 847-850
27. Takada, S., Stark, K. L., Shea, M. J., Vassileva, G., McMahon, J. A., and McMahon, A. P. (1994) Genes Dev. 8, 174-189
28. Nakayama, A., Nguyen, M. T., Chen, C. C., Opdecamp, K., Hodgkinson, C. A., and Arnheiter, H. (1998) Mech. Dev. 70, 155-166
29. Eastman, Q., and Grosschedl, R. (1999) Curr. Opin. Cell Biol. 11, 233-240
30. Shibamoto, S., Higano, K., Takada, R., Ito, F., Takeichi, M., and Takada, S. (1998) Genes Cells 3, 659-670
31. Bennett, D. C., Cooper, P. J., and Hart, I. R. (1987) Int. J. Cancer 39, 414-418
32. Tachibana, M., Perez-Jurado, L. A., Nakayama, A., Hodgkinson, C. A., Li, X., Schneider, M., Miki, T., Fex, J., Francke, U., and Arnheiter, H. (1994) Hum. Mol. Genet. 3, 553-557
33. Ercolani, L., Florence, B., Denaro, M., and Alexander, M. (1988) J. Biol. Chem. 263, 15335-15341
34. Waterman, M. L., Fischer, W. H., and Jones, K. A. (1991) Genes Dev. 5, 656-669
35. van de Wetering, M., Cavallo, R., Dooijes, D., van Beest, M., van Es, J., Loureiro, J., Ypma, A., Hursh, D., Jones, T., Bejsovec, A., Peifer, M., Mortin, M., and Clevers, H. (1997) Cell 88, 789-799
36. Rubinfeld, B., Robbins, P., El-Gamil, M., Albert, I., Porfiri, E., and Polakis, P. (1997) Science 275, 1790-1792
37. Dorsky, R. I., Raible, D. W., and Moon, R. T. (2000) Genes Dev. 14, 158-162
38. Price, E. R., Horstmann, M. A., Wells, A. G., Weilbaecher, K. N., Takemoto, C. M., Landis, M. W., and Fisher, D. E. (1998) J. Biol. Chem. 273, 33042-33047


Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Hum Mol GenetHome page
I. Matera, D. E. Watkins-Chow, S. K. Loftus, L. Hou, A. Incao, D. L. Silver, C. Rivas, E. C. Elliott, L. L. Baxter, and W. J. Pavan
A sensitized mutagenesis screen identifies Gli3 as a modifier of Sox10 neurocristopathy
Hum. Mol. Genet., July 15, 2008; 17(14): 2118 - 2131.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
J. N. Dynek, S. M. Chan, J. Liu, J. Zha, W. J. Fairbrother, and D. Vucic
Microphthalmia-Associated Transcription Factor Is a Critical Transcriptional Regulator of Melanoma Inhibitor of Apoptosis in Melanomas
Cancer Res., May 1, 2008; 68(9): 3124 - 3132.
[Abstract] [Full Text] [PDF]


Home page
Genes Dev.Home page
V. Delmas, F. Beermann, S. Martinozzi, S. Carreira, J. Ackermann, M. Kumasaka, L. Denat, J. Goodall, F. Luciani, A. Viros, et al.
beta-Catenin induces immortalization of melanocytes by suppressing p16INK4a expression and cooperates with N-Ras in melanoma development
Genes & Dev., November 15, 2007; 21(22): 2923 - 2935.
[Abstract] [Full Text] [PDF]


Home page
J BiochemHome page
K. Takeda, T. Adachi, F. Han, S. Yokoyama, H. Yamamoto, W. Hida, and S. Shibahara
Augmented Chemosensitivity in Black-Eyed White Mitf mi-bw Mice, Lacking Melanocytes
J. Biochem., March 1, 2007; 141(3): 327 - 333.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
A. Schepsky, K. Bruser, G. J. Gunnarsson, J. Goodall, J. H. Hallsson, C. R. Goding, E. Steingrimsson, and A. Hecht
The Microphthalmia-Associated Transcription Factor Mitf Interacts with {beta}-Catenin To Determine Target Gene Expression
Mol. Cell. Biol., December 1, 2006; 26(23): 8914 - 8927.
[Abstract] [Full Text] [PDF]


Home page
DevelopmentHome page
T. J. Carney, K. A. Dutton, E. Greenhill, M. Delfino-Machin, P. Dufourcq, P. Blader, and R. N. Kelsh
A direct role for Sox10 in specification of neural crest-derived sensory neurons
Development, December 1, 2006; 133(23): 4619 - 4630.
[Abstract] [Full Text] [PDF]


Home page
J BiochemHome page
S. Yokoyama, K. Takeda, and S. Shibahara
Functional Difference of the SOX10 Mutant Proteins Responsible for the Phenotypic Variability in Auditory-Pigmentary Disorders
J. Biochem., October 1, 2006; 140(4): 491 - 499.
[Abstract] [Full Text] [PDF]


Home page
Genes Dev.Home page
L. Chin, L. A. Garraway, and D. E. Fisher
Malignant melanoma: genetics and therapeutics in the genomic era.
Genes & Dev., August 15, 2006; 20(16): 2149 - 2182.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
C. Goding and F. L. Meyskens Jr.
Microphthalmic-Associated Transcription Factor Integrates Melanocyte Biology and Melanoma Progression
Clin. Cancer Res., February 15, 2006; 12(4): 1069 - 1073.
[Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
K. Koyanagi, S. J. O'Day, R. Gonzalez, K. Lewis, W. A. Robinson, T. T. Amatruda, C. Kuo, H.-J. Wang, R. Milford, D. L. Morton, et al.
Microphthalmia Transcription Factor as a Molecular Marker for Circulating Tumor Cell Detection in Blood of Melanoma Patients
Clin. Cancer Res., February 15, 2006; 12(4): 1137 - 1143.
[Abstract] [Full Text] [PDF]


Home page
DevelopmentHome page
J. Voigt and N. Papalopulu
A dominant-negative form of the E3 ubiquitin ligase Cullin-1 disrupts the correct allocation of cell fate in the neural crest lineage
Development, February 1, 2006; 133(3): 559 - 568.
[Abstract] [Full Text] [PDF]


Home page
DevelopmentHome page
M. Osawa, G. Egawa, S.-S. Mak, M. Moriyama, R. Freter, S. Yonetani, F. Beermann, and S.-I. Nishikawa
Molecular characterization of melanocyte stem cells in their niche
Development, December 15, 2005; 132(24): 5589 - 5599.
[Abstract] [Full Text] [PDF]


Home page
Sci SignalHome page
L. Sommer
Checkpoints of Melanocyte Stem Cell Development
Sci. Signal., August 23, 2005; 2005(298): pe42 - pe42.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
M. Ji and O. M. Andrisani
High-Level Activation of Cyclic AMP Signaling Attenuates Bone Morphogenetic Protein 2-Induced Sympathoadrenal Lineage Development and Promotes Melanogenesis in Neural Crest Cultures
Mol. Cell. Biol., June 15, 2005; 25(12): 5134 - 5145.
[Abstract] [Full Text] [PDF]


Home page
J. Cell Biol.Home page
Y. Yamaguchi, S. Itami, H. Watabe, K.-i. Yasumoto, Z. A. Abdel-Malek, T. Kubo, F. Rouzaud, A. Tanemura, K. Yoshikawa, and V. J. Hearing
Mesenchymal-epithelial interactions in the skin: increased expression of dickkopf1 by palmoplantar fibroblasts inhibits melanocyte growth and differentiation
J. Cell Biol., April 26, 2004; 165(2): 275 - 285.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
J. Goodall, S. Martinozzi, T. J. Dexter, D. Champeval, S. Carreira, L. Larue, and C. R. Goding
Brn-2 Expression Controls Melanoma Proliferation and Is Directly Regulated by {beta}-Catenin
Mol. Cell. Biol., April 1, 2004; 24(7): 2915 - 2922.
[Abstract] [Full Text] [PDF]


Home page
DevelopmentHome page
J. L. Lewis, J. Bonner, M. Modrell, J. W. Ragland, R. T. Moon, R. I. Dorsky, and D. W. Raible
Reiterated Wnt signaling during zebrafish neural crest development
Development, March 15, 2004; 131(6): 1299 - 1308.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
C. Doglioni, S. Piccinin, S. Demontis, M. G. Cangi, L. Pecciarini, C. Chiarelli, M. Armellin, T. Vukosavljevic, M. Boiocchi, and R. Maestro
Alterations of {beta}-Catenin Pathway in Non-Melanoma Skin Tumors: Loss of {alpha}-ABC Nuclear Reactivity Correlates with the Presence of {beta}-Catenin Gene Mutation
Am. J. Pathol., December 1, 2003; 163(6): 2277 - 2287.
[Abstract] [Full Text]


Home page
J. Biol. Chem.Home page
W. E. Huber, E. R. Price, H. R. Widlund, J. Du, I. J. Davis, M. Wegner, and D. E. Fisher
A Tissue-restricted cAMP Transcriptional Response: SOX10 MODULATES {alpha}-MELANOCYTE-STIMULATING HORMONE-TRIGGERED EXPRESSION OF MICROPHTHALMIA-ASSOCIATED TRANSCRIPTION FACTOR IN MELANOCYTES
J. Biol. Chem., November 14, 2003; 278(46): 45224 - 45230.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pathol.Home page
K Pham, T Milovanovic, R J Barr, T Truong, and R F Holcombe
Wnt ligand expression in malignant melanoma: pilot study indicating correlation with histopathological features
Mol. Pathol., October 1, 2003; 56(5): 280 - 285.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
I. J. Davis, B.-L. Hsi, J. D. Arroyo, S. O. Vargas, Y. A. Yeh, G. Motyckova, P. Valencia, A. R. Perez-Atayde, P. Argani, M. Ladanyi, et al.
Cloning of an Alpha-TFEB fusion in renal tumors harboring the t(6;11)(p21;q13) chromosome translocation
PNAS, May 13, 2003; 100(10): 6051 - 6056.
[Abstract] [Full Text] [PDF]


Home page
J. Cell Biol.Home page
L. Hari, V. Brault, M. Kleber, H.-Y. Lee, F. Ille, R. Leimeroth, C. Paratore, U. Suter, R. Kemler, and L. Sommer
Lineage-specific requirements of {beta}-catenin in neural crest development
J. Cell Biol., December 9, 2002; 159(5): 867 - 880.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
Z.-X. Jin, H. Kishi, X.-C. Wei, T. Matsuda, S. Saito, and A. Muraguchi
Lymphoid Enhancer-Binding Factor-1 Binds and Activates the Recombination-Activating Gene-2 Promoter Together with c-Myb and Pax-5 in Immature B Cells
J. Immunol., October 1, 2002; 169(7): 3783 - 3792.
[Abstract] [Full Text] [PDF]


Home page
J. Cell Biol.Home page
H. R. Widlund, M. A. Horstmann, E. R. Price, J. Cui, S. L. Lessnick, M. Wu, X. He, and D. E. Fisher
{beta}-Catenin-induced melanoma growth requires the downstream target Microphthalmia-associated transcription factor
J. Cell Biol., September 16, 2002; 158(6): 1079 - 1087.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. Khaled, L. Larribere, K. Bille, E. Aberdam, J.-P. Ortonne, R. Ballotti, and C. Bertolotto
Glycogen Synthase Kinase 3beta Is Activated by cAMP and Plays an Active Role in the Regulation of Melanogenesis
J. Biol. Chem., September 6, 2002; 277(37): 33690 - 33697.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. Filali, N. Cheng, D. Abbott, V. Leontiev, and J. F. Engelhardt
Wnt-3A/beta -Catenin Signaling Induces Transcription from the LEF-1 Promoter
J. Biol. Chem., August 30, 2002; 277(36): 33398 - 33410.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
H. Saito, K.-i. Yasumoto, K. Takeda, K. Takahashi, A. Fukuzaki, S. Orikasa, and S. Shibahara
Melanocyte-specific Microphthalmia-associated Transcription Factor Isoform Activates Its Own Gene Promoter through Physical Interaction with Lymphoid-enhancing Factor 1
J. Biol. Chem., August 2, 2002; 277(32): 28787 - 28794.
[Abstract] [Full Text] [PDF]